Atypical Femur Fractures

2022 ◽  
pp. 715-734
Author(s):  
Yasser El Miedany
Keyword(s):  
Femur Fractures ◽  
Atypical Femur Fractures

Bisphosphonates and the risk of atypical femur fractures

Bone ◽  
2021 ◽  
pp. 116297
Author(s):  
Dennis M. Black ◽  
Katherine Condra ◽  
Richard Eastell
Keyword(s):  
Femur Fractures ◽  
Atypical Femur Fractures

Trabecular Bone Score and Hip Structural Analysis in Patients With Atypical Femur Fractures

2019 ◽  
Vol 22 (2) ◽  
pp. 257-265 ◽  
Author(s):  
Sanne K.C. Buitendijk ◽  
Denise M. van de Laarschot ◽  
Alexandra A.A. Smits ◽  
Fjorda Koromani ◽  
Fernando Rivadeneira ◽  
...  
Keyword(s):  
Structural Analysis ◽  
Trabecular Bone ◽  
Trabecular Bone Score ◽  
Hip Structural Analysis ◽  
Femur Fractures ◽  
Atypical Femur Fractures

Atypical Femur Fractures

2014 ◽  
Vol 28 ◽  
pp. S36-S42 ◽  
Author(s):  
Joseph Borrelli ◽  
Joseph Lane ◽  
Susan Bukata ◽  
Kenneth A. Egol ◽  
Richelle Takemoto ◽  
...  
Keyword(s):  
Femur Fractures ◽  
Atypical Femur Fractures

scholarly journals Long-term risks of bisphosphonate therapy

2014 ◽  
Vol 58 (5) ◽  
pp. 523-529 ◽  
Author(s):  
Nelson B. Watts
Keyword(s):  
Lower Risk ◽  
Observational Studies ◽  
Osteonecrosis Of The Jaw ◽  
Bisphosphonate Therapy ◽  
Safety Issues ◽  
Femur Fractures ◽  
Atypical Femur Fractures ◽  
Post Marketing ◽  
Risk Patients

The objective this study was to summarize long-term risks associated with bisphosphonate therapy. Search of relevant medical publications for data from clinical trials, trial extensions, observational studies and post-marketing reports. Trial extensions and modifications did not reveal significant long-term safety issues. Observational data suggest at least as many benefits as risks. Post-marketing reports of musculoskeletal pain, osteonecrosis of the jaw and atypical femur fractures have been widely circulated in the lay press. Most focus on long-terms risks has been on osteonecrosis of the jaw and atypical femur fractures which occur in patients who have not received bisphosphonate therapy but may be more frequent (though still uncommon) in patients who have been on treatment for 5 years or longer. Lower-risk patients may be able to stop treatment after 3-5 years for a “drug holiday,” which mitigates these long-term risks; for higher risk patients, therapy through 6-10 years appears to be advisable and offers more benefits than risks.

Detection of Incomplete Non-Displaced Atypical Femur Fractures by Densitometer

2014 ◽  
Vol 17 (3) ◽  
pp. 418 ◽  
Author(s):  
A.M. Cheung ◽  
R. Bleakney ◽  
R. Ridout ◽  
H. McDonald-Blumer ◽  
D. Yau ◽  
...  
Keyword(s):  
Femur Fractures ◽  
Atypical Femur Fractures

Risk factors for atypical femur fractures in cancer patients.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e12533-e12533
Author(s):  
Beatrice J. Edwards ◽  
Huifang Lu ◽  
Mimi I-Nan Hu ◽  
Smita Saraykar ◽  
Andrew Bunta ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cancer Patients ◽  
Femur Fractures ◽  
Atypical Femur Fractures
Sign in / Sign up

Export Citation Format

Share Document